Review anchor
Alpha-1A adrenergic receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
Evidence Snapshot
Alpha-1A adrenergic receptor
CHEMBL229
SINGLE PROTEIN
Homo sapiens
Identity Layer
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Alpha-1A adrenergic receptor as ChEMBL target CHEMBL229, mapped to UniProt P35348. Disease framing currently uses the Open Targets-ready proxy contract.
ChEMBL target ID
CHEMBL229
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine
As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P35348
Alpha-1A adrenergic receptor
UniProt accession via ChEMBL component mapping
As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy
As of 2026-09-13
www.ebi.ac.uk
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Review-ready Target Rationale
Why Alpha-1A adrenergic receptor matters
Alpha-1A adrenergic receptor is reviewed as Alpha-1A adrenergic receptor (UniProt P35348); Alpha-1A adrenergic receptor shows approved-linked disease relevance led by benign prostatic hyperplasia. 5 more disease programs remain visible in the same review block.; 1 linked drug keep this evidence frame grounded.; the current evidence base includes 69 approved drugs, 4996 compounds, and 645 assays, with lead potency reaching pChEMBL 11.0.
Protein context
Alpha-1A adrenergic receptor
Alpha-1A adrenergic receptor Sequence length is 466 aa.
Review this target as Alpha-1A adrenergic receptor, mapped to UniProt P35348. Sequence length is 466 aa.
Protein source · UniProt accession via ChEMBL component mapping
UniProt P35348
Protein
Disease context
benign prostatic hyperplasia
Alpha-1A adrenergic receptor shows approved-linked disease relevance led by benign prostatic hyperplasia. 5 more disease programs remain visible in the same review block. 1 linked drug keep the rationale reviewable. 5 additional disease programs remain visible in the same card. Linked drugs include SILODOSIN.
Start review with benign prostatic hyperplasia because it currently carries approved-linked support. Linked drugs include SILODOSIN. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target record
Approved-linked
1 linked drug
Activity base
Portfolio and assay base
ChEMBL currently tracks 69 approved drugs, 4996 compounds, and 645 assays for this target. The dominant activity type is KI. CHEMBL145843 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL145843 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core Engine
69 approved
pChEMBL 11.0
Source Guidance
Start with the right source
Pick the first block or linked source that matches the review question in front of you.
Need the shortest review narrative first?
Review-ready Target Rationale
One-page rationale with as-of-date and attribution
Start with the review rationale when you need to explain why Alpha-1A adrenergic receptor matters before drilling into raw source blocks.
Jump to Review RationaleNeed stable protein naming or accession mapping?
UniProt Target Context
UniProt accession via ChEMBL component mapping
Go back to the target snapshot when you need the naming and mapping contract behind UniProt P35348, not just the summarized rationale.
Open Protein ContextNeed disease fit or evidence level for program framing?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy
Use the target snapshot disease block when you need to see why benign prostatic hyperplasia is currently treated as approved-linked support.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
4996
Total Compounds
645
Total Assays
69
Approved Drugs
IC50: 377.0, KI: 2081.0, EC50: 362.0, KD: 23.0
Activity Types
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL145843
|
11.0 | Ki | — |
|
|
No preferred name
CHEMBL145547
|
10.7 | Ki | — |
|
|
No preferred name
CHEMBL10085
|
10.7 | Ki | Clinical |
|
|
No preferred name
CHEMBL836
|
10.5 | Ki | Approved |
|
|
No preferred name
CHEMBL24778
|
10.4 | Ki | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
LUMATEPERONE TOSYLATE
CHEMBL3233142
|
2019 |
|
|
CARIPRAZINE HYDROCHLORIDE
CHEMBL2024517
|
2015 |
|
|
BREXPIPRAZOLE
CHEMBL2105760
|
2015 |
|
|
VILAZODONE HYDROCHLORIDE
CHEMBL1615374
|
2011 |
|
|
INDACATEROL
CHEMBL1095777
|
2009 |
|
|
SILODOSIN
CHEMBL24778
|
2008 |
|
|
PALIPERIDONE
CHEMBL1621
|
2006 |
|
|
ALFUZOSIN
CHEMBL709
|
2003 |
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
ZIPRASIDONE
CHEMBL708
|
2001 |
|
|
DEXMEDETOMIDINE HYDROCHLORIDE
CHEMBL2106195
|
1999 |
|
|
NAFTOPIDIL
CHEMBL142635
|
1999 |
|
|
DEXMEDETOMIDINE
CHEMBL778
|
1999 |
|
|
QUETIAPINE
CHEMBL716
|
1997 |
|
|
TAMSULOSIN
CHEMBL836
|
1997 |
|
|
AZELASTINE HYDROCHLORIDE
CHEMBL1200809
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
AZELASTINE
CHEMBL639
|
1996 |
|
|
SALMETEROL
CHEMBL1263
|
1994 |
|
|
NEFAZODONE HYDROCHLORIDE
CHEMBL1200492
|
1994 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
DOXAZOSIN
CHEMBL707
|
1990 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
PERGOLIDE
CHEMBL531
|
1988 |
|
|
TERAZOSIN
CHEMBL611
|
1987 |
|
|
OXYMETAZOLINE
CHEMBL762
|
1986 |
|
|
METHOXAMINE
CHEMBL524
|
1982 |
|
|
BROMOCRIPTINE
CHEMBL493
|
1978 |
|
|
PRAZOSIN
CHEMBL2
|
1976 |
|
|
PRAZOSIN HYDROCHLORIDE
CHEMBL1558
|
1976 |
|
|
CLONIDINE HYDROCHLORIDE
CHEMBL1705
|
1974 |
|
|
CLONIDINE
CHEMBL134
|
1974 |
|
|
NAPHAZOLINE
CHEMBL761
|
1971 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
EPINEPHRINE
CHEMBL679
|
1965 |
|
|
FLUPHENAZINE
CHEMBL726
|
1959 |
|
|
PHENTOLAMINE
CHEMBL597
|
1952 |
|
|
PHENYLEPHRINE
CHEMBL1215
|
1952 |
|
|
NOREPINEPHRINE
CHEMBL1437
|
1950 |
|
|
DIHYDROERGOTAMINE MESYLATE
CHEMBL1200517
|
1946 |
|
|
MIANSERIN
CHEMBL6437
|
— |
Source Header